Traders Purchase Large Volume of Edwards Lifesciences Call Options (NYSE:EW)

Key Points

• Traders have purchased a notable volume of 22,451 call options for Edwards Lifesciences, reflecting a 657% increase compared to the average daily volume.
• Insider sales were reported, with VP Daniel J. Lippis selling 4,114 shares and Larry L. Wood selling 8,950 shares, indicating a decrease in ownership by insiders.
• Edwards Lifesciences reported a net margin of 72.96% and surpassed earnings expectations with $0.67 earnings per share in its latest quarterly results.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders acquired 22,451 call options on the stock. This is an increase of 657% compared to the average daily volume of 2,966 call options.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of EW. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the 1st quarter valued at approximately $26,000. SouthState Corp bought a new position in Edwards Lifesciences in the 1st quarter worth approximately $27,000. Rosenberg Matthew Hamilton bought a new position in Edwards Lifesciences in the 2nd quarter worth approximately $28,000. Tradewinds Capital Management LLC boosted its holdings in Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after buying an additional 205 shares during the period. Finally, Rossby Financial LCC bought a new position in Edwards Lifesciences in the 1st quarter worth approximately $29,000. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on EW. Mizuho boosted their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. Wall Street Zen downgraded shares of Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research report on Monday, September 29th. Finally, Truist Financial boosted their target price on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average target price of $87.06.

Edwards Lifesciences Stock Up 0.8%

Edwards Lifesciences stock traded up $0.60 during midday trading on Monday, hitting $75.24. 1,310,991 shares of the stock were exchanged, compared to its average volume of 4,448,080. Edwards Lifesciences has a 52-week low of $64.89 and a 52-week high of $83.00. The stock has a market capitalization of $44.17 billion, a price-to-earnings ratio of 10.82, a price-to-earnings-growth ratio of 3.58 and a beta of 1.05. The business's 50-day moving average price is $77.54 and its 200-day moving average price is $76.21. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same period in the previous year, the company earned $0.70 earnings per share. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts expect that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.